Caricamento...
Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
Tyrosine kinase inhibitors (TKIs) targeting signaling molecules downstream B cell receptor (BCR) are powerfully spreading in the therapeutic landscape of B cell lymphoproliferative disease, due to a manageable toxicity profile and encouraging clinical effectiveness. In particular, ibrutinib, previou...
Salvato in:
| Pubblicato in: | J Hematol Oncol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4459446/ https://ncbi.nlm.nih.gov/pubmed/26022368 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0157-x |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|